Exicure Seeks Votes to Sell Up to $10M of Stock at Up to a 25% Discount and Double Authorized Shares
XCUR sits 21% above its 52-week low of $0.875.
Summary
Exicure's preliminary proxy asks shareholders to approve up to $10 million of private placements at as little as 75% of the Nasdaq Minimum Price, double authorized shares to 400 million, and adopt a new equity plan reserving 15% of shares outstanding. All of it goes to a vote on December 2, 2026, as the company runs low on cash.
Key Events · Financing and Capital Events · XCUR
-
Up to $10M Private Placement Authorized
Proposal 3 would let Exicure issue more than 20% of its outstanding stock in private placements over the three months after approval, for maximum aggregate gross proceeds of up to $10,000,000.
-
Units Priced at 25% Discount Floor
Each unit is one share plus three five-year warrants, priced at the lesser of $1.30 or 75% of the Nasdaq Minimum Price at signing; warrants strike at no less than 110% of the unit price, so shares issued or issuable can reach four times the units sold.
-
Authorized Shares Would Double
Proposal 5 raises authorized common stock from 200,000,000 to 400,000,000 shares (total authorized capital from 210,000,000 to 410,000,000); no shares are issued by the amendment itself.
-
New Equity Plan Reserves 15% of Shares
The 2026 Omnibus Incentive Plan reserves 981,899 shares, equal to 15% of the 6,545,995 shares outstanding as of October 27, 2026, with an annual evergreen increase back to 15%.
Analysis · XCUR · Life Sciences
Shareholders are being asked to pre-approve a private placement of up to $10 million, and the terms carry a built-in discount of at least 25% to the market floor: units are priced at the lesser of $1.30 per unit or 75% of the Nasdaq Minimum Price at signing. Each unit carries one share plus three five-year warrants struck at 110% of the unit price, so the share count issued or issuable can reach four times the number of units sold. Against 6,545,995 shares outstanding, the 20%-plus issuance this authorizes is heavily dilutive. At the same time, the company is asking to double authorized common stock to 400 million shares and to reserve 981,899 shares (15% of shares outstanding) for a new equity plan. The backdrop is tight: the Q2 2026 10-Q showed $1.7M of cash, stockholders' equity below Nasdaq's minimum and a going concern warning, with a December 2, 2026 compliance deadline already extended by Nasdaq. The vote is the gate — without it, the company says its financing alternatives would be severely limited.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XCUR was trading at $1.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.7M. The 52-week trading range was $0.88 to $9.48. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.